Changes in Clinical Outcomes and Peripheral Cytokines during Duloxetine Add‐on Therapy in Parkinson's Disease
Movement Disorders Clinical Practice · 2026-11-05
DOI: 10.1002/mdc3.70885 ↗Abstract
Abstract Background Neuroinflammation is implicated in Parkinson's disease (PD), and antidepressants may have anti‐inflammatory and motor benefits. The effects of duloxetine on inflammatory biomarkers and clinical outcomes in PD remain unclear. Objectives To assess changes in motor symptoms, quality of life, and serum cytokines during add‐on duloxetine treatment in PD. Methods Seventeen patients with PD without other chronic inflammatory diseases received add‐on duloxetine for 8 weeks in an open‐label, uncontrolled trial. Clinical outcomes included Unified Parkinson's Disease Rating Scale (UPDRS), modified Hoehn and Yahr (HY), and Parkinson's Disease Questionnaire‐39 (PDQ‐39) scores. Serum TNF‐α, IL‐1β, IL‐6, and IL‐10 levels were measured at baseline and follow‐up. Results UPDRS, activities of daily living, and PDQ‐39 scores decreased during treatment. Ten patients achieved ≥5‐point UPDRS reductions. TNF‐α, IL‐1β, and IL‐6 decreased, whereas IL‐10 increased after treatment. Conclusions Add‐on duloxetine was associated with changes in clinical outcomes and inflammatory markers in patients with PD.
EUVIMED